GoodRx Holdings (GDRX) Cost of Revenue (2019 - 2026)

GoodRx Holdings has disclosed Cost of Revenue across 8 years of filings, most recently posting $21.0 million for Q2 2026.

• In Q2 2026, Cost of Revenue rose 57.3% year-over-year to $21.0 million; the TTM figure through Jun 2026 stood at $72.0 million (up 42.39% YoY), while the FY2025 annual figure was $57.6 million, up 19.46% from the prior year.
• Cost of Revenue came in at $21.0 million for Q2 2026 at GoodRx Holdings, up from $20.2 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $21.0 million in Q2 2026 to a low of $11.7 million in Q3 2024.
• Average Cost of Revenue over 5 years is $15.5 million, with a median of $15.8 million recorded in 2023.
• Year-over-year, Cost of Revenue surged 62.71% in 2022 and plunged 37.59% in 2024.
• Over 5 years, Cost of Revenue stood at $17.4 million in 2022, then dropped by 12.62% to $15.2 million in 2023, then slipped by 19.62% to $12.2 million in 2024, then jumped by 43.23% to $17.5 million in 2025, then gained by 20.24% to $21.0 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $21.0 million in Q2 2026, $20.2 million in Q1 2026, and $17.5 million in Q4 2025.